SCHEMBL1647327

SCHEMBL1647327

O=Cc1ccccc1S(=O)(=O)Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.52
KMT2A Q03164 3/20 0.52
LMNA P02545 2/20 0.52
MEN1 O00255 2/20 0.52
THRB P10828 1/20 0.52
BLM P54132 1/20 0.52
ALDH1A1 P00352 6/20 0.43
TSHR P16473 2/20 0.43
TRIM24 O15164 1/20 0.43
TRIM33 Q9UPN9 1/20 0.43
HSD17B10 Q99714 1/20 0.41
HTT P42858 2/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NFE2L2 Q16236 4/20 0.38
GAA P10253 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
ERN1 O75460 1/20 0.35
PADI4 Q9UM07 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29849654 1.00 TDP1 (0.52) TDP1KMT2ALMNAMEN1THRB
SCHEMBL9357011 0.84 TDP1 (0.42) TDP1KMT2ALMNAMEN1THRB
SCHEMBL1005794 0.80 ALDH1A1 (0.46) TDP1KMT2ALMNAMEN1THRB
SCHEMBL5095373 0.80 TDP1 (0.39) TDP1KMT2ALMNAMEN1THRB
SCHEMBL11055574 0.80 TDP1 (0.39) TDP1KMT2ALMNAMEN1THRB
SCHEMBL5252641 0.79 LMNA (0.55) TDP1KMT2ALMNAMEN1THRB
SCHEMBL536001 0.77 LMNA (0.52) TDP1KMT2ALMNAMEN1THRB
SCHEMBL31598826 0.77 MEN1 (0.52) TDP1KMT2ALMNAMEN1THRB
SCHEMBL5088711 0.77 MEN1 (0.52) TDP1KMT2ALMNAMEN1THRB
SCHEMBL40458 0.77 TDP1 (0.52) TDP1KMT2ALMNAMEN1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110105280-B Water-soluble fluorescent probe based on 1, 8-naphthalimide and preparation method and application thereof 佛山市格瑞芬新能源有限公司 2022-06-17 CN claimed
CN-109761930-B Fluorescent switch and preparation method and application thereof 中国科学院福建物质结构研究所 2020-12-29 CN claimed
CN-116730944-B Saccharin preparation method 北京惠宇乐邦环保科技有限公司 2023-11-17 CN disclosed
CN-116730944-A Saccharin preparation method 北京惠宇乐邦环保科技有限公司 2023-09-12 CN disclosed
US-20230142739-A1 PROTEIN-PROTEIN INTERACTION STABILIZERS UNIV CALIFORNIA (US) 2023-05-11 US disclosed
EP-4125861-A2 PROTEIN-PROTEIN INTERACTION STABILIZERS The Regents of the University of California (US) 2023-02-08 EP disclosed
WO-2022266711-A1 SUBSTITUTED AMIDOBENZIMIDAZOLE DIMERS AS STING MODULATORS Aculeus Therapeutics Pty Ltd (AU) 2022-12-29 WO disclosed
WO-2022266711-A1 SUBSTITUTED AMIDOBENZIMIDAZOLE DIMERS AS STING MODULATORS Aculeus Therapeutics Pty Ltd (AU) 2022-12-29 WO disclosed
CN-110105280-B Water-soluble fluorescent probe based on 1, 8-naphthalimide and preparation method and application thereof 佛山市格瑞芬新能源有限公司 2022-06-17 CN disclosed
WO-2021203016-A2 PROTEIN-PROTEIN INTERACTION STABILIZERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-10-07 WO disclosed
CN-109761930-B Fluorescent switch and preparation method and application thereof 中国科学院福建物质结构研究所 2020-12-29 CN disclosed
EP-1194429-A1 POTASSIUM CHANNEL OPENERS Abbott Laboratories (US) 2002-04-10 EP disclosed
US-6214882-B1 Benzenesulphonamide derivatives, preparation thereof and therapeutical uses thereof SYNTHELABO (FR) 2001-04-10 US disclosed
WO-2000078768-A1 POTASSIUM CHANNEL OPENERS ABBOTT LABORATORIES (US) 2000-12-28 WO disclosed
EP-0613468-B1 Substituted salicylic acids for the treatment of autoimmune diseases PHARMACIA & UPJOHN AB (SE) 2000-07-12 EP disclosed
US-5556855-A TREATMENT OF AUTOIMMUNE DISEASES PHARMACIA AB (SE) 1996-09-17 US disclosed
US-5403930-A Chemical intermediate for drugs used in autoimmune diseases PHARMACIA AB (SE) 1995-04-04 US disclosed
EP-0613468-A1 NOVEL SUBSTITUTED SALICYCLIC ACIDS Pharmacia & Upjohn Aktiebolag (SE) 1994-09-07 EP disclosed
US-5302718-A Used for treating autoimmune diseases KABI PHARMACIA AB (SE) 1994-04-12 US disclosed
WO-1993010094-A1 NOVEL SUBSTITUTED SALICYCLIC ACIDS KABI PHARMACIA AB (SE) 1993-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230142739-A1 PROTEIN-PROTEIN INTERACTION STABILIZERS HSPBP1, HSPA8, HSPH1 TDP1 2335/4885KMT2A 3385/4885LMNA 2827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.